Industry Wire 214

September 27, 2024 Jake Fishman 0 min read
  1. LAPD officer’s gun sucked into MRI machine during raid.
  2. Dems introduce legislation to permanently lower ACA plan costs. 
  3. Cardinal Health acquires Integrated Oncology Network for $1B.
  4. CDC: 40.3% of U.S adults are obese, 46.5% of adults aged 40-59.
  5. VA’s new Oracle EHR saw 826 ‘major’ incidents since its launch.
  6. U.S. House committee passes rare pediatric disease drug bill.
  7. 29% of Americans have undiagnosed iron deficiency.
  8. Senate holds Steward Health CEO in criminal contempt.
  9. PA-based system fires workers for sharing inappropriate patient images.
  10. Providers say reimbursement denials are getting worse.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Structural Heart May 14, 2026

The Young TAVR Trend is Stabilizing May 14, 2026

Despite a TAVR popularity surge in recent years, a Vizient registry analysis suggests the procedure’s prevalence has stabilized in patients under 65, but there’s still significant debate on whether the young patient TAVR rate is appropriate.

Cardiovascular Disease May 11, 2026

BP Lowering Still Decreases CVD Risk Even in CKD May 11, 2026

Data from a new Lancet study suggests that patients with chronic kidney disease (CKD) might get similar cardiovascular protection from blood pressure drugs as the general population, giving physicians some certainty about how to approach BP in these patients.

Cardiology Pharmaceuticals May 7, 2026

Aficamten, ACACIA-HCM, and the Road to the First nHCM Drug May 7, 2026

The question of how to treat non-obstructive hypertrophic cardiomyopathy has long perplexed researchers and pharmaceutical developers alike, but topline results from Cytokinetics’ Phase 3 ACACIA-HCM trial suggest MYQORZO (aficamten) could be the answer.